These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 4070284)

  • 1. The design and development of therapeutic agents for neuromuscular diseases.
    Lewis NJ
    Prog Clin Biol Res; 1985; 197():105-10. PubMed ID: 4070284
    [No Abstract]   [Full Text] [Related]  

  • 2. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.
    Engstrom LO
    Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295
    [No Abstract]   [Full Text] [Related]  

  • 3. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
    Finkel MJ
    Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of voluntary disease organizations in research and development of orphan drugs.
    Horansky R
    Prog Clin Biol Res; 1985; 197():179-81. PubMed ID: 4070293
    [No Abstract]   [Full Text] [Related]  

  • 5. The National Cancer Institute's Drug Development Program.
    Schepartz SA
    Prog Clin Biol Res; 1985; 197():73-82. PubMed ID: 4070301
    [No Abstract]   [Full Text] [Related]  

  • 6. Orphan drug development in the United States.
    Groft SC
    CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Antiepileptic Drug Development Program: an example of government-industry collaboration.
    White BG
    Prog Clin Biol Res; 1985; 197():83-93. PubMed ID: 4070302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular medicine. NIH dives into drug discovery.
    Couzin J
    Science; 2003 Oct; 302(5643):218-21. PubMed ID: 14551416
    [No Abstract]   [Full Text] [Related]  

  • 9. The Orphan Products Board of the Department of Health & Human Services.
    Crooks GM
    Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294
    [No Abstract]   [Full Text] [Related]  

  • 10. NIH gives money for orphan development.
    Watanabe ME
    Nat Med; 2000 Nov; 6(11):1197-8. PubMed ID: 11062512
    [No Abstract]   [Full Text] [Related]  

  • 11. Orphan products activities of the National Institutes of Health.
    Schepartz SA
    Prog Clin Biol Res; 1983; 127():173-86. PubMed ID: 6889399
    [No Abstract]   [Full Text] [Related]  

  • 12. The development of orphan drugs--a pharmaceutical company perspective.
    Stucki JC
    Prog Clin Biol Res; 1985; 197():95-104. PubMed ID: 4070303
    [No Abstract]   [Full Text] [Related]  

  • 13. The antibiotic pipeline.
    Montgomery AB
    N Engl J Med; 2004 Nov; 351(19):2019-20. PubMed ID: 15529454
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug development for orphan diseases in the context of personalized medicine.
    Brewer GJ
    Transl Res; 2009 Dec; 154(6):314-22. PubMed ID: 19931198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why academic drug discovery makes sense.
    Kozikowski AP; Roth B; Tropsha A
    Science; 2006 Sep; 313(5791):1235-6. PubMed ID: 16946051
    [No Abstract]   [Full Text] [Related]  

  • 16. Rare diseases: identifying needs. Report of the National Commission on Orphan Diseases.
    Groft SC
    Am Pharm; 1990 Apr; NS30(4):33-40. PubMed ID: 2321528
    [No Abstract]   [Full Text] [Related]  

  • 17. Generic Pharmaceutical Industry Association Orphan Drug Institute.
    Haddad W
    Prog Clin Biol Res; 1985; 197():41-5. PubMed ID: 4070298
    [No Abstract]   [Full Text] [Related]  

  • 18. The Pharmaceutical Manufacturers Association Commission on Drugs for Rare Diseases.
    Goldstein GS
    Prog Clin Biol Res; 1985; 197():35-9. PubMed ID: 4070297
    [No Abstract]   [Full Text] [Related]  

  • 19. Orphan Drug Act on congressional agenda.
    von Oehsen WH
    Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
    Dorfman HL; Reig LP
    Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.